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greater for patients  6 40 years (three-category kappa = 0.67) 
than for younger patients (kappa = 0.49). In addition, the 
agreement was significantly lower for patients with atypical 
mole syndrome (AMS) (kappa = 0.31) than for patients with-
out AMS (kappa = 0.76).  Limitations: The data were limited 
by the inclusion/exclusion criteria of the MelaFind  study. 
This might represent a selection bias. The agreement was 
evaluated using kappa statistics. This is a standard method 
for evaluating agreement among pathologists, but might be 
considered controversial by some statisticians.  Conclusions: 
Expert dermatopathologists have a high level of agreement 
when diagnosing clinically difficult melanocytic lesions. 
However, even among expert dermatopathologists, the cur-
rent ‘gold standard’ is not perfect. Our results indicate that 
lesions from younger patients and patients with AMS may be 
more problematic for the dermatopathologists, suggesting 
that improved diagnostic criteria are needed for such pa-
tients.  Copyright © 2012 S. Karger AG, Basel 
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 Abstract 
 Background: The ‘gold standard’ for the diagnosis of mela-
nocytic lesions is dermatopathology. Although most of the 
diagnostic criteria are clearly defined, the interpretation of 
histopathology slides may be subject to interobserver vari-
ability.  Objectives: The aim of this study was to determine 
the variability among dermatopathologists in the interpre-
tation of clinically difficult melanocytic lesions.  Methods: 
This study used the database of MelaFind  , a computer-vi-
sion system for the diagnosis of melanoma. All lesions were 
surgically removed and sent for independent evaluation by 
four dermatopathologists. Agreement was calculated using 
kappa statistics.  Results: A total of 1,249 pigmented melano-
cytic lesions were included. There was a substantial agree-
ment among expert dermatopathologists: two-category 
kappa was 0.80 (melanoma vs. non-melanoma) and three-
category kappa was 0.62 (malignant vs. borderline vs. be-
nign melanocytic lesions). The agreement was significantly 
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 Introduction 
 Accurate interpretation of the histopathology of biop-
sied specimens is essential in directing appropriate pa-
tient management, that is how the patients are informed, 
treated and followed up. In addition, the final pathology 
diagnosis, whether correct or not, is ultimately respon-
sible for determining which lesions enter into cancer reg-
istry databases  [1] . This in turn may influence the results 
of epidemiological investigations of cancer, diagnostic 
studies, or comparative studies that rely upon evaluations 
provided by pathologists  [2–5] .
 Evidence-based medicine requires that the perfor-
mance of a diagnostic test be compared to a reference 
standard (i.e. ‘gold standard’)  [6] . In dermatology, clinical 
studies designed to evaluate the performance of diagnos-
tic tests, such as clinical examination, dermoscopic ex-
amination, or computer-assisted diagnosis, require that 
the results be compared to a reference standard. This ‘ref-
erence’ or ‘gold’ standard is currently the dermatopatho-
logical diagnosis  [2, 7, 8] , based mainly on visual inter-
pretation of formalin-fixed histological slides of the biop-
sied tissue. Although most of the diagnostic criteria for 
differentiating melanocytic lesions are clearly defined, 
the interpretation of the histopathology slides may be 
subject to interobserver variability since it relies on sub-
jective evaluation of tissue morphology and of cytological 
atypia. The aim of this study was to determine the degree 
of interobserver variability among dermatopathologists 
in the interpretation of clinically difficult to diagnose 
melanocytic lesions of the skin.
 Materials and Methods 
 This study utilized the MelaFind  database. MelaFind  is a 
computer-vision system designed by MELA Sciences, Inc. (MELA) 
to identify lesions to be biopsied to rule out melanoma; clinical 
testing of this system has been recently completed  [9, 10] . Data for 
this study were collected prospectively at multiple clinical sites in 
the U.S., Switzerland, Austria, and Australia. According to the 
MelaFind  study protocol, all patients (without age limit) sched-
uled for the surgical removal of any pigmented skin lesion which 
met the inclusion criteria were eligible to participate in this study. 
The inclusion criteria required that the pigmented lesion (mela-
nocytic or non-melanocytic) be between 2 and 22 mm in diameter 
and be devoid of ulceration, bleeding, or foreign matter (e.g. tat-
toos). Furthermore, lesions on mucosa or in subungual regions 
were excluded.
 For each case, the following clinical information was recorded: 
patient age, gender, anatomic location of the lesion, and pre-biop-
sy clinical and dermoscopic diagnosis rendered by the examining 
dermatologist at the time of examination. The clinician was re-
quested to select from the following diagnostic possibilities: ‘mel-
anoma’, ‘melanoma cannot be ruled out’, or ‘not melanoma’. If the 
lesion was not felt to be melanoma but still removed, the clinician 
was asked to record the reason for biopsy. The lesions were surgi-
cally removed and subjected to routine histopathology processing 
at the treating physician’s preferred dermatopathology laboratory. 
The diagnostic histological slides were subsequently sent to MELA 
for independent histopathological evaluation by a panel of four 
dermatopathologists. The data from five clinical sites (AC, RB, 
RHW, DP, HR) were used in the present study. Since our focus was 
the diagnosis of melanocytic lesions, all other lesions (e.g. basal 
cell carcinoma, pigmented seborrheic keratosis, etc.) were exclud-
ed from this study, based on the final histological interpretation. 
Each histopathology case was examined independently by two 
study dermatopathologists out of a panel of four experts (M.M., 
P.G., R.K., V.G.P.). The diagnosis of the local pathologist was not 
recorded or taken into account for the purpose of this study and 
only the diagnoses of the study pathologists were recorded and 
used in the development of the computer-vision system.
 The four study dermatopathologists did not partake in any 
formal or informal training or consensus meeting at any time for 
the purpose of this study. However, it should be acknowledged 
that two of the study dermatopathologists were trained by Dr. 
Mihm (Dr. Googe about 20 years ago and Dr. King about 10 years 
ago), and that Dr. Mihm evaluated all cases while each of the re-
maining study dermatopathologists evaluated about 1/3 of the 
cases. 
 The histopathological diagnosis was ultimately used as the ref-
erence standard for the evaluation of the diagnostic performance 
of the computer-vision system  [11] . In case of significant discor-
dance between the first two dermatopathologists, the histological 
slide was independently reviewed by a third study pathologist. 
According to our definition ‘significant discordance’ occurred if 
one study pathologist read a slide as MM or HGDN (positive di-
agnosis) and the second pathologist read it as LGDN or OTHER 
(negative diagnosis). The dermatopathologists were completely 
blinded to the pre-biopsy diagnosis, originating laboratory pa-
thology diagnosis, patient demographics such as age, or diagnosis 
made by other study pathologists. In addition, the pathologists 
were unaware whether the case was being reviewed as a regular 
evaluation or due to discordance between the first two study pa-
thologists.
 Interobserver agreement was evaluated using the kappa statis-
tic and kappa values were compared using a   2 test, as defined by 
Fleiss  [12] . For interpretation of the kappa values, we used the sys-
Table 1. I nterpretation of kappa values according to Landis and 
Koch [13]
Kappa Interpretation
<0 no agreement
0.00–0.20 slight agreement
0.21–0.40 fair agreement
0.41–0.60 moderate agreement
0.61–0.80 substantial agreement
0.81–1.00 almost perfect agreement
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tem proposed by Landis and Koch  [13] ( table 1 ). Weighted kappa 
values were used to take into account the fact that discordance of 
diagnoses such as melanoma versus junctional nevus is clinically 
much more important than the discordance of diagnoses such as 
melanoma in situ versus HGDN or HGDN versus LGDN. In ad-
dition, such values allow a comparison of our results with the re-
sults previously reported in the literature that were based on the 
weighted kappa statistics. While kappa statistics have been criti-
cized in the literature  [14, 15] , they are recommended for the study 
of observer agreement by others  [16, 17] .
 Results 
 A total of 1,249 melanocytic pigmented lesions from 
five clinical sites matched the inclusion criteria for this 
study ( table 2 ). The final histological diagnoses were es-
tablished as follows. A lesion was considered (1) mela-
noma if at least one (blindly verified) diagnosis was mel-
anoma, (2) HGDN if at least two diagnoses were HGDN, 
or (3) OTHER in the remaining cases. Only 190 cases 
(15.2%) were considered ‘not melanoma’ and 97 cases 
(7.8%) were considered ‘melanoma’ prior to biopsy by the 
examining dermatologists. The remaining lesions were 
biopsied due to suspicion of melanoma (i.e. ‘melanoma 
cannot be ruled out’). Thus, almost 80% of lesions in-
cluded in the study were difficult to diagnose both clini-
cally and dermoscopically. The percentages of histologi-
cally confirmed melanomas among lesions with the clin-
ical diagnoses of ‘melanoma’, ‘melanoma cannot be ruled 
out’, and ‘not melanoma’ were 82.5, 11.5, and 2.6%, re-
spectively.
 Of the 1,249 lesions, 129 (10.3%) required an evalua-
tion by a third study panel dermatopathologist because of 
significant discordance, as defined above. All other cases 
had concordant histopathological diagnoses indicating a 
good level of agreement among dermatopathologists. 
Kappa statistics were utilized to analyze agreement, and 
since results depend on the number of categories and the 
prevalence of these categories in the database, we evalu-
ated kappa for several types of stratification of the data. 
Since ten different comparisons were made in this study, 
we adopted the conservative Bonferroni method so that 
each test is considered statistically significant if p  ! 0.005 
 [17] .
 First, we calculated kappa values for two categories: 
‘melanoma’ (invasive or in situ) and ‘non-melanoma’ 
(HGDN/AMP/AMH, LGDN, and other benign nevi). 
The corresponding kappa values for these two categories 
are shown in  table  3 . We found excellent agreement 
among dermatopathologists for the diagnosis of mela-
noma versus non-melanoma, with an overall kappa value 
of 0.80. The agreement among dermatopathologists was 
found to be greater if the patient’s age was  6 40 years
(p = 0.03, but not statistically significant for multiple 
comparisons). 
 Next, we determined the agreement between derma-
topathologists using three categories: ‘MALIGNANT’ 
(in situ melanoma, invasive melanoma), ‘UNCERTAIN’ 
(HGDN/AMP/AMH), and ‘BENIGN’ lesions (all other 
melanocytic neoplasms). The corresponding kappa val-
ues are shown in  table 4 . The overall kappa value was 0.62, 
indicating substantial agreement. As expected, an in-
crease in the number of categories leads to a decrease in 
kappa values. 
 Although agreement was slightly better for lesions 
with a definite pre-biopsy diagnosis as rendered by the 
Table 2. S ummary of the final histological diagnoses in the data-
base
Lesion type Cases Prevalence
Melanoma, invasive
BT median = 0.44 mm
BT range 0.15–5.00 mm
116 9.3%
Melanoma, in situ 80 6.4%
Nevus, high-grade dysplastic/AMP/AMH 75 6.0%
Nevus, low-grade dysplastic 747 59.8%
Nevus, blue 20 1.6%
Nevus, congenital 46 3.7%
Nevus, Spitz 10 0.8%
Nevus, other 155 12.4%
Total 1,249 100.0%
AMH = Atypical melanocytic hyperplasia; AMP = atypical 
melanocytic proliferation; BT = Breslow thickness.
Table 3. K appa statistics for two categories: ‘melanoma’ (invasive 
or in situ) and ‘non-melanoma’ (HGDN/AMP/AMH, LGDN, and 
other benign nevi)
Type Subtype Cases Kappa (95% CI) p
All 1,249 0.80 (0.75–0.86)
Patient age, 
years
1–40 594 0.69 (0.61–0.77) 0.03>40 655 0.82 (0.74–0.90)
Patient sex female 592 0.84 (0.76–0.92) 0.27male 657 0.77 (0.70–0.85)
Pre-biopsy
diagnosis
definite 287 0.83 (0.72–0.95) 0.34suspicious 962 0.77 (0.70–0.83)
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examining dermatologist (melanoma or not melanoma) 
than for lesions having an unclear pre-biopsy diagnosis 
(‘melanoma cannot be ruled out’), this did not meet sta-
tistical significance.
 Once again, the overall agreement was greater for pa-
tients  6 40 years (kappa = 0.67) as compared to younger 
patients (kappa = 0.49), and this was statistically highly 
significant (p  ! 0.0005). Among younger patients, there 
were 111 (19%) lesions with at least one positive (mela-
noma or HGDN) pathological diagnosis and 75 (68%) of 
these lesions had discordant diagnoses. Among older pa-
tients, there were 229 (35%) lesions with at least one pos-
itive diagnosis and 98 (43%) of these lesions had discor-
dant diagnoses. Thus, the kappa statistic does differenti-
ate between patients with low and high agreement of 
pathological diagnoses. 
 Since actinic damage of the skin may influence the in-
terpretation of the histopathology, we compared the data 
from different clinical centers separately. The data showed 
no significant difference in variability of diagnosis be-
tween clinical centers having many patients with sun-
damaged skin as compared to clinical centers with few 
such patients: for the two Florida sites (538 cases), the 
two-category kappa (melanoma vs. not melanoma) was 
0.79 while for the other three sites (711 cases) it was 0.80. 
Thus, our data showed no significant difference in the 
variability of diagnosis between sites with many patients 
having sun-damaged skin compared to sites with few 
such patients.
 In addition, we also retrospectively evaluated all cases 
submitted by HR and RB to determine whether the pa-
tients had the atypical mole syndrome (AMS) or not. We 
used the definition of AMS given by Kopf et al.  [18, 19] : 
‘Patients with 100 or more melanocytic nevi, one or more 
melanocytic nevi at least 8 mm in maximum diameter, 
and one or more nevi with clinical atypical features.’ 
Overall there were 212 cases with AMS and 146 cases 
without AMS at these two sites; for some patients the 
AMS status was not known and these cases were exclud-
ed from the analysis. The corresponding kappa values are 
shown in  table 5 . The kappa values indicate that patho-
logical agreement was substantially lower for specimens 
derived from patients with AMS (kappa = 0.31) as com-
pared to patients without AMS (kappa = 0.76); the differ-
ence is highly significant (p  ! 0.001).
 In the corresponding subgroup analysis, we found that 
for patients with AMS, the agreement was still signifi-
cantly lower for the younger patients ( ! 40 years). For pa-
tients without AMS the difference in pathological agree-
ment was not significantly different for younger and older 
patients. This could be partially due to the small sample 
size (50 patients  ! 40 years, 96 patients  6 40 years). Our 
results suggest that the agreement among dermatopathol-
ogists depends on both patient’s age and patient’s AMS 
status.
 Lastly, we analyzed agreement for five categories of 
histopathological diagnosis: MM invasive, MM in situ, 
HGDN/AMP/AMH, LGDN, and OTHER. The results are 
shown in  table 6 , where prevalence denotes frequency of 
the diagnosis rather than final histological diagnosis. We 
found the highest agreement for invasive melanoma 
(kappa = 0.74) and second highest for melanoma in situ 
(kappa = 0.54). The agreement was lowest for high-grade 
dysplastic nevi and it was slightly higher for low-grade 
dysplastic nevi. The overall kappa values indicate moder-
ate agreement. 
 In statistics ‘weighting’ is used to account for the fact 
that not all disagreements are of equal clinical impor-
tance; for example, a disagreement on two diagnoses such 
as melanoma vs. junctional nevus would be clinically 
much more relevant than the disagreement of diagnoses 
Table 4. K appa statistics for three categories: ‘MALIGNANT’ (in 
situ and invasive melanoma), ‘UNCERTAIN’ (HGDN/AMP/
AMH), and ‘BENIGN’ (all other benign melanocytic neoplasms)
Type Subtype Cases Kappa (95% CI) p
All 1,249 0.62 (0.58–0.67)
Patient age, 
years
1–40 594 0.49 (0.43–0.55) <0.0001>40 655 0.67 (0.61–0.73)
Patient sex female 592 0.67 (0.61–0.73) 0.06male 657 0.59 (0.53–0.65)
Pre-biopsy 
diagnosis
definite 287 0.68 (0.59–0.78) 0.07suspicious 962 0.59 (0.54–0.65)
Table 5.  Kappa statistics for three categories (MM, HGDN/AMP/
AMH, and OTHER) for patients with and without AMS
AMS status Cases Kappa p
With AMS 212 0.31 <0.0001Without AMS 146 0.76
With AMS ≤40 years 155 0.07 0.001With AMS >40 years 57 0.48
Without AMS ≤40 years 50 0.56 0 .12Without AMS >40 years 96 0.79
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such as melanoma in situ vs. HGDN or HGDN vs. LGDN. 
In our analysis we used two different types of weighting. 
Both Cohen’s and Cichetti-Allison’s weighting formulas 
 [12] indicate substantial agreement between the study 
dermatopathologists.
 In addition to considering invasive versus in situ mel-
anomas, it would also be of interest to consider thick 
melanomas ( 1 1 mm in thickness) vs. thin melanomas (in 
situ and  ^  1 mm in thickness). However, the data set of 
1,249 melanocytic lesions includes only 17 lesions with 
at least one histological diagnosis of thick melanoma and 
this sample is too small for kappa statistics. Further-
more, two of these cases have only one determination of 
thickness. For the remaining cases of thick melanoma, 
the concordance rate was 80% (12 out of 15.) Among 179 
lesions with at least one histological diagnosis of thin 
melanoma, the concordance rate was 70% (125 out of 
179.) The rate of concordance was not significantly dif-
ferent for thin or thick melanomas, with p = 0.56 by Fish-
er’s exact test.
 Discussion 
 Evidence-based medicine requires that new diagnos-
tic tests must be compared to the currently accepted ref-
erence standard (i.e. ‘gold standard’) in order to deter-
mine the new test’s performance and merit. Therefore, 
new diagnostic techniques utilized for the diagnosis of 
melanocytic neoplasms, such as dermoscopy, confocal 
microscopy, and machine-vision, just to mention a few, 
have generally been compared to dermatopathology, 
which is currently considered the gold standard. We are 
convinced that the ‘true gold standard’ in cancer diag-
nosis is not a diagnostic test but the malignant behavior 
of the neoplasm. Even if a gold standard classifies a le-
sion as benign, the occurrence of metastatic behavior 
will prove the gold standard wrong. However, even 
though the diagnostic criteria for melanoma are well es-
tablished in dermatopathology, it is important to ac-
knowledge that this gold standard is based on visual ex-
amination of tissue morphology and cytological atypia, 
which, like any other visual evaluation, is open to sub-
jective interpretation. Dermatopathology is subject to 
interobserver variability. With that being said, one of 
the quandaries in evidence-based medicine is determin-
ing how and when it is permissible to overrule the gold 
standard or when is it time to replace the gold standard 
with a better one. In other words, if a new diagnostic test 
outperforms the current gold standard, how is it possi-
ble to prove that the new test is in fact superior to the 
current standard? For example, let us assume that the 
lesion under investigation is biologically a melanoma. If 
a diagnostic method renders a diagnosis of melanoma 
and the dermatopathologist renders a diagnosis of be-
nign nevus, evidence-based medicine may classify the 
lesion as benign, when in fact it is melanoma, and the 
result of the new instrument will be considered false 
positive. Rarely is consideration given to the fact that a 
diagnostic method may potentially be superior to the 
current gold standard. 
 Since more and more non-invasive technologies and 
new in vivo and ex vivo tests for melanoma are emerging, 
we felt that there was a need to take a closer look at what 
is currently considered to be the gold standard for the di-
agnosis of melanoma. We therefore investigated the de-
gree of interobserver agreement for the histopathological 
diagnosis of difficult melanocytic neoplasms by expert 
dermatopathologists. We used the MelaFind  database, 
since the data have been collected prospectively in differ-
ent centers under routine clinical conditions, and the his-
topathological evaluation was performed by a panel of 
dermatopathologists. This setting provided data that 
were ideal for the purpose of this study. 
 Since our focus was the diagnosis of melanocytic le-
sions, we excluded all other lesions (e.g. basal cell carci-
noma, pigmented seborrheic keratosis, etc.). We included 
the data from five clinical sites, which together contrib-
uted most of the cases in the MelaFind  database. The 
clinical sites were either specialized referral centers or pig-
mented skin lesion clinics (RB, DP, RHW) or private prac-
tices specializing in the diagnosis and treatment of skin 
cancers (AC, HR). All five centers see mainly high-risk 
melanoma patients such as those with AMS, previous his-
Table 6. K appa statistics for five categories: MM invasive, MM in 
situ, HGDN/AMP/AMH, LGDN, and OTHER
Diagnosis category Prevalence Kappa (95% CI)
MM invasive 7.2% 0.74 (0.68–0.79)
MM in situ 5.5% 0.54 (0.49–0.60)
HGDN/AMP 9.4% 0.24 (0.18–0.29)
LGDN 47.7% 0.32 (0.27–0.38)
OTHER 30.2% 0.38 (0.33–0.44)
OVERALL, unweighted 0.39 (0.36–0.42)
OVERALL, weight w1 0.79 (0.72–0.85)
OVERALL, weight w2 0.61 (0.56–0.66)
W eights w1 and w2 are according to Cohen and Cicchetti-
Allison, respectively.
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tory of skin cancer, family history of melanoma, etc. From 
our own experience, we are of the opinion that the pig-
mented lesions in many of these high-risk patients are 
more difficult to diagnose because many of their benign 
nevi manifest clinical and/or dermoscopic features of 
melanoma or their melanomas manifest subtle features 
that make their detection a challenge. Cuellar et al. re-
cently reported that in fair-skinned individuals early mel-
anomas can be difficult to diagnose  [20] . Thus, the 
MelaFind  database is biased towards lesions with a high-
er degree of diagnostic difficulty as compared to lesions 
encountered in the setting of a general dermatology office.
 To our knowledge, this is the first large-scale study 
(n = 1,249 lesions) of the agreement among dermatopa-
thologists for the diagnosis of clinically difficult melano-
cytic neoplasms. Even though the lesions were of a high 
degree of diagnostic difficulty, only 10.3% required a 
third evaluation by a study dermatopathologist. The in-
terobserver agreement among expert dermatopatholo-
gists was found to be better than reported previously in 
the literature, and we found that the results of the litera-
ture were contradictory, most likely due to different selec-
tion biases in different studies.
 In a recent retrospective study, Shoo et al. found dis-
cordant diagnoses in 14.3% of 392 cases referred to a 
specialized center  [21] . This might represent a selection 
bias because it is likely that only the most difficult cases 
are referred for second opinion. As a consequence, the 
agreement will be low due to the selection of difficult 
lesions. In order to avoid this potential bias we included 
every biopsied lesion from the study sites. In addition, 
our study pathologists were all expert dermatopatholo-
gists specialized in the diagnosis of melanocytic neo-
plasms. This explains the higher agreement rate in our 
study. 
 In another study reported by Farmer et al., 37 histo-
logical slides were evaluated by eight pathologists and the 
results recorded in three categories (benign, malignant, 
and indeterminate)  [22] . They found a combined kappa 
of 0.50, as compared to 0.62 in our study.
 In a publication by Duncan et al., the interobserver 
agreement based on 60 melanocytic lesions revealed kap-
pa values between 0.55 and 0.84 for the analysis in two 
categories (melanoma vs. not melanoma)  [23] .
 Another study by Corona et al. used 140 slides (main-
ly melanoma with a small subset of benign pigmented le-
sions) and found a kappa of 0.61  [24] as compared to 0.80 
in our study. In conclusion, the authors found ‘consider-
able disagreement among pathologists on the diagnosis 
of melanoma versus other pigmented lesions’.
 Cook et al. reported the results of a study of 95 histo-
logical slides of thin melanomas that had been read by 
eight pathologists. The two-category kappa in this study 
was 0.77  [25] .
 Ferrara et al. investigated interobserver agreement 
based on 107 cases of dermoscopically and histopatho-
logically equivocal melanocytic lesions and found an 
overall kappa of 0.74. In their initial pilot study from 36 
possible pairs of observers, 8 pairs showed a kappa  1 0.75; 
19 showed a kappa  1 0.5 and 17 had a kappa  ! 0.5, indicat-
ing fair to moderate agreement  [26, 27] .
 In the present study, based on the analysis of 1,249 le-
sions, the overall kappa was 0.80. It is important to men-
tion that there was no initial meeting or consensus con-
ference between the study dermatopathologists and that 
they were totally blinded to the clinical diagnosis, level of 
clinical suspicion, or patient demographics while evalu-
ating the pathology slides. Furthermore, there was abso-
lutely no exchange of information between the study der-
matopathologists regarding the study. This is an impor-
tant point since such communications could have created 
a consensus among the pathologists on how to interpret 
and diagnose the pathology slides, thereby leading to an 
artificially high concordance. With that being said, we do 
need to acknowledge that some of the study pathologists 
had worked together previously and this may have par-
tially contributed to the high agreement rate. The alterna-
tive, and perhaps more likely, explanation as to why the 
agreement in our study was high is that all the study der-
matopathologists are experts specializing in the diagno-
sis of skin cancers.
 An important point is the nature and number of the 
different diagnostic categories used for the classification 
of melanocytic neoplasms. According to different schools 
and concepts in histopathology there are different types 
of categories. This issue has been addressed by Zembo-
wicz and Scolyer  [28] in a recent review article. The au-
thors came to the conclusion that it was more appropriate 
to expand the classification scheme of melanocytic neo-
plasms rather than to narrow it. This strongly supports 
the classification used in this study ( table 2 ).
 Considering different diagnostic categories, we found 
that agreement was highest for the diagnosis of invasive 
melanoma (kappa = 0.74), second highest for melanoma 
in situ (kappa = 0.54) and worst for high-grade dysplastic 
nevi (kappa = 0.24) ( table 6 ). This confirms the observa-
tion made by Duncan et al.  [23] that the histopathology 
concordance for the different grades of dysplastic nevi 
was rather poor. The agreement was very good for the 
majority of cases and rather poor in the remaining chal-
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lenging cases. Our findings suggest that the category of 
high-grade dysplastic nevi had the largest number of 
challenging cases.
 The agreement of the dermatopathologists was better 
if the clinician was sure of his clinical diagnosis (either 
melanoma or non-melanoma). If the pre-biopsy diagno-
sis was ‘melanoma cannot be ruled out’, indicating that 
the clinician was not sure whether the lesion was in fact 
benign or not, the agreement among the pathologists was 
poorer, but the difference was not statistically signifi-
cant. Ferrara et al. looked at the concordance of dermos-
copy and histopathology and came to similar conclu-
sions  [26, 27] . If different dermoscopists agreed on the 
dermoscopic diagnosis, different dermatopathologists 
also tended to agree on the histopathology diagnosis and 
vice versa. 
 To our knowledge, none of the previous studies looked 
at other parameters such as patient age or gender. It is in-
teresting that the agreement of the dermatopathological 
diagnosis was significantly higher in patients  6 40 years. 
Our first hypothesis was that with increasing age, pa-
tients might have more cumulative sun exposure and sun 
damage and that the sun damage may somehow account 
for the higher concordance. Two of the study sites are lo-
cated in Florida (AC, HR) where even younger patients 
( ! 40 years) already manifest extensive sun damage. On 
the other hand, the other study sites (RB, RHW and DP) 
are located in geographic areas where patients have much 
less sun exposure and manifest less sun damage. There 
was no significant difference between agreement at the 
sites in different geographical areas.
 Our next hypothesis was that most of the younger pa-
tients seen in these specialized referral centers were at 
high risk for developing melanoma and that a significant 
proportion of them may manifest the AMS. Based on 
this premise, at two study sites (RB and HR), the princi-
pal investigators went back to the charts of all patients 
enrolled in this study and recorded if the patients had 
AMS or not; patients with unknown AMS status were 
excluded from the analysis. We compared the patholog-
ical kappa values for patients with (n = 212) and without 
(n = 146) AMS and found that kappa was significantly 
lower for patients with AMS (kappa = 0.31) as compared 
to patients without AMS (kappa = 0.76) (p  ! 0.0001). 
Thus, our data indicate that lesions from patients with 
AMS may be more problematic for the pathologists, ac-
counting for the lower agreement among the dermatopa-
thologists. However, within the subgroup of AMS pa-
tients, the agreement was still significantly lower for the 
younger patients.
 In our opinion, these findings could be explained by 
timing of nevogenesis and senescence  [29–33] . The pro-
cess of nevogenesis in non-AMS individuals appears to be 
more frequent and more dynamic in youth. By the time 
individuals are in their fourth decade of life, most nevi 
have entered into a senescent state and the frequency of 
developing new or enlarging nevi becomes much lower 
 [29, 34, 35] . In contrast, the nevogenesis process may be 
more exuberant in individuals with AMS. Thus, in addi-
tion to developing numerous new nevi in adolescence and 
youth, many patients with AMS continue to develop new 
and growing nevi in older age. These new nevi, which 
have not yet undergone senescence, may manifest a vari-
ety of atypical morphologies, which in turn may explain 
the observed poorer agreement among the study patholo-
gists  [29] . Although this remains a conjecture, our study 
clearly indicates that agreement among pathologists was 
poorer in patients  ! 40 years and in patients manifesting 
AMS. 
 Conclusions 
 Expert dermatopathologists have a high level of agree-
ment when diagnosing clinically difficult melanocytic 
lesions. However, even though this agreement is very 
good, it is not 100%. Thus, even among expert dermato-
pathologists, the current ‘gold standard’ is not perfect 
and this fact needs to be addressed when deciding on pa-
tient management or when evaluating new diagnostic 
methods. Furthermore, this study highlights the fact 
that any discipline that relies on the visual evaluation of 
tissue morphology for rendering a diagnosis, whether 
clinical, dermoscopic, radiological or histological, must 
contend with interobserver disagreements, due to dif-
ferences of perception or differences in interpretation. 
Therefore, clinicians must reconcile the clinical and his-
tological information, obtain second opinions when ap-
propriate, and ultimately assimilate all the information 
in a manner that allows for the formulation of a reason-
able management plan that keeps the best interest of the 
patient foremost. Nevertheless, until proven otherwise, 
histopathology remains the best method available at this 
time for rendering an accurate diagnosis of melanocytic 
neoplasms.
 While agreement of histological diagnoses by expert 
dermatopathologists is very good, it is significantly poor-
er for younger patients and for patients with AMS. There-
fore, the results of this study suggest that improved diag-
nostic criteria are needed for these patients. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
15
/2
01
6 
5:
57
:4
8 
PM
 Braun et al. 
 
Dermatology 2012;224:51–5858
 Acknowledgements 
 The authors thank MELA Sciences, Inc. for releasing data for 
this study, and Joanna Adrian, Mrinalini Roy, and Nikolai Ka-
belev of MELA for help with data management. The work of Dr. 
Braun and Dr. Kolm was supported by an Oncosuisse grant as well 
as by the Swiss National Foundation. The authors declare no oth-
er funding.
 Disclosure Statement 
 D.G.K. is an employee of MELA Sciences, Inc.; M.M., V.G.P., 
P.G. and R.K. were the dermatopathologists for the MelaFind  
study; R.P.B., I.K., H.R., M.O., A.C., D.P., R.H.W. and V.A.S. were 
investigators in the MelaFind  study. There are no conflicts of 
interest relevant for this study.
 
 References 
 1 Thompson B, Austin R, Coory M, Aitken JF, 
Walpole E, Francis G, Fritschi L: Complete-
ness of histopathology reporting of melano-
ma in a high-incidence geographical region. 
Dermatology 2009; 218: 7–14. 
 2 Mayer J: Systematic review of the diagnostic 
accuracy of dermatoscopy in detecting ma-
lignant melanoma. Med J Aust 1997; 167: 
 206–210. 
 3 Lock-Andersen J, Hou-Jensen K, Hansen J, 
Jensen N, Sogaard H, Andersen P: Observer 
variation in histological classification of cu-
taneous malignant melanoma. Scand J Plast 
Reconstr Surg Hand Surg 1995; 29: 141–148. 
 4 Busam K, Antonescu C, Marghoob M, Nehal 
K, Sachs D, Shia J, Berwick M: Histologic 
classification of tumor-infiltrating lympho-
cytes in primary cutaneous malignant mela-
noma. A study of interobserver agreement. 
Am J Clin Pathol 2001; 115: 856–860. 
 5 Oliveria S, Dusza S, Berwick M: Issues in the 
epidemiology of melanoma. Expert Rev An-
ticancer Ther 2001; 1: 453–459. 
 6 Sackett DL, Straus SE, Richardson WS, 
Rosenberg W, Haynes RB: Evidence-Based 
Medicine: How to Practice and Teach EBM. 
Edinburgh/New York, Churchill Living-
stone, 2000. 
 7 Kittler H, Pehamberger H, Wolff K, Binder 
M: Diagnostic accuracy of dermoscopy. Lan-
cet Oncol 2002; 3: 159–165. 
 8 Vestergaard M, Macaskill P, Holt P, Menzies 
SW: Dermoscopy compared with naked eye 
examination for the diagnosis of primary 
melanoma: a meta-analysis of studies per-
formed in a clinical setting. Br J Dermatol 
2008; 159: 669–676. 
 9 Elbaum M, Kopf AW, Rabinovitz HS, et 
al: Automatic differentiation of melanoma 
from melanocytic nevi with multispectral 
digital dermoscopy: a feasibility study. J Am 
Acad Dermatol 2001; 44: 207–218. 
 10 Friedman RJ, Gutkowicz-Krusin D, Farber 
MJ, et al: The diagnostic performance of ex-
pert dermoscopists vs a computer-vision sys-
tem on small-diameter melanomas. Arch 
Dermatol 2008; 144: 476–482. 
 11 Monheit G, Cognetta AB, Ferris L, et al: 
The performance of MelaFind: a prospec-
tive multicenter study. Arch Dermatol 2011; 
 147: 188–194. 
 12 Fleiss JL: Statistical Methods for Rates and 
Proportions. New York, John Wiley, 1981. 
 13 Landis JR, Koch GG: The measurement of 
observer agreement for categorical data. Bio-
metrics 1977; 33: 159–174. 
 14 Uebersax JS: Diversity of decision-making 
models and the measurement of interrater 
agreement. Psychol Bull 1987; 101: 140–146. 
 15 Uebersax JS: Modeling approaches for the 
analysis of observer agreement. Invest Ra-
diol 1992; 27: 738–743. 
 16 Kundel HL, Polansky M: Measurement of 
observer agreement. Radiology 2003; 228: 
 303–308. 
 17 Fisher LD: Biostatistics. New York, Wiley, 
1993. 
 18 Marghoob AA, Kopf AW, Rigel DS, et 
al: Risk of cutaneous malignant melanoma 
in patients with ‘classic’ atypical-mole syn-
drome. A case-control study. Arch Dermatol 
1994; 130: 993–998. 
 19 Kopf AW, Friedman RJ, Rigel DS: Atypical 
mole syndrome. J Am Acad Dermatol 1990; 
 22: 117–118. 
 20 Cuellar F, Puig S, Kolm I, Puig-Butille S, 
Zaballos P, Marti-Laborda R, Badenas C, 
Malvehy J: Dermoscopic features of melano-
mas associated with MC1R variants in Span-
ish CDKN2A mutation carriers. Br J Derma-
tol 2009; 160: 48–53. 
 21 Shoo BA, Sagebiel RW, Kashani-Sabet M: 
Discordance in the histopathologic diagno-
sis of melanoma at a melanoma referral cen-
ter. J Am Acad Dermatol 2010; 62: 751–756. 
 22 Farmer ER, Gonin R, Hanna MP: Discordance 
in the histopathologic diagnosis of melanoma 
and melanocytic nevi between expert patholo-
gists. Hum Pathol 1996; 27: 528–531. 
 23 Duncan L, Berwick M, Bruijn J, Byers H, 
Mihm M, Barnhill R: Histopathologic recog-
nition and grading of dysplastic melanocytic 
nevi: an interobserver agreement study. J In-
vest Dermatol 1993; 100: 318S–321S. 
 24 Corona R, Mele A, Amini M, et al: Interob-
server variability on the histopathologic di-
agnosis of cutaneous melanoma and other 
pigmented skin lesions. J Clin Oncol 1996; 
 14: 1218–1223. 
 25 Cook M, Clarke T, Humphreys S, et al: The 
evaluation of diagnostic and prognostic cri-
teria and the terminology of thin cutaneous 
malignant melanoma by the CRC Melanoma 
Pathology Panel. Histopathology 1996; 28: 
 497–512. 
 26 Ferrara G, Argenziano G, Soyer HP, et al: 
Dermoscopic and histopathologic diagnosis 
of equivocal melanocytic skin lesions: an in-
terdisciplinary study on 107 cases. Cancer 
2002; 95: 1094–1100. 
 27 Ferrara G, Argenziano G, Soyer HP, et al: 
Histopathologic interobserver agreement on 
the diagnosis of melanocytic skin lesions 
with equivocal dermoscopic features: a pilot 
study. Tumori 2000; 86: 445–449. 
 28 Zembowicz A, Scolyer RA: Nevus/melano-
cytoma/melanoma: an emerging paradigm 
for classification of melanocytic neoplasms? 
Arch Pathol Lab Med 2011; 135: 300–306. 
 29 Grichnik J: Melanoma, nevogenesis, and 
stem cell biology. J Invest Dermatol 2008; 
 128: 2365–2380. 
 30 Zalaudek I, Hofmann-Wellenhof R, Soyer 
HP, Ferrara G, Argenziano G: Naevogenesis: 
new thoughts based on dermoscopy. Br J 
Dermatol 2006; 154: 793–794. 
 31 Zalaudek I, Ferrara G, Argenziano G: Der-
moscopy insights into nevogenesis: ‘Abtrop-
fung’ versus ‘Hochsteigerung’. Arch Derma-
tol 2007; 143: 284. 
 32 Zalaudek I, Marghoob AA, Scope A, Hof-
mann-Wellenhof R, Ferrara G, Argenziano 
G: Age distribution of biopsied junctional 
nevi – Unna’s concept versus a dual concept 
of nevogenesis. J Am Acad Dermatol 2007; 
 57: 1096–1097. 
 33 Zalaudek I, Hofmann-Wellenhof R, Kittler 
H, et al: A dual concept of nevogenesis: theo-
retical considerations based on dermoscopic 
features of melanocytic nevi. J Dtsch Derma-
tol Ges 2007; 5: 985–992. 
 34 Aguilera P, Puig S: Clinical and dermoscopic 
features of nevi in children. Dermatology 
2010;220:54. 
 35 Barnhill RL: Melanocytic nevi and tumor 
progression: perspectives concerning histo-
morphology, melanoma risk and molecular 
genetics. Dermatology 1993; 187: 86–90. 
 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
15
/2
01
6 
5:
57
:4
8 
PM
